NEW YORK (360Dx) – With US Food and Drug Administration clearance in hand for its bacterial urinary tract infection testing platform, BacterioScan is focused on its commercial launch.

The company announced earlier this week that its system, called 216Dx, received FDA clearance. Providing results within three hours, the platform could address the fast-growing problem of antibiotic resistance.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.